A randomised trial of vitamin D in acute‐stage allergic bronchopulmonary aspergillosis complicating asthma. Issue 4 (5th February 2019)

• Record Type: Journal Article
• Authors: Dodamani, Manjunath Havalappa; Muthu, Valliappan; Thakur, Reetu; Pal, Arnab; Sehgal, Inderpaul Singh; Dhooria, Sahajal; Aggarwal, Ashutosh N.; Garg, Mandeep; Chakrabarti, Arunaloke; Agarwal, Ritesh
• Is Part Of: Mycoses. Volume 62:Issue 4(2019)
• Page Start: 320
• Page End: 327
• Publication Date: 2019-02-05
• Subjects: ABPM -- asthma exacerbation -- cholecalciferol -- immunotherapy -- severe asthma; Pathogenic fungi -- Periodicals; Medical mycology -- Periodicals; 616.969
• DOI: 10.1111/myc.12879
• Languages: English
• ISSNs: 0933-7407

Abstract

Summary: Vitamin D has been demonstrated to have an immunomodulatory role in cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA). Herein, we evaluate supplemental vitamin D in acute‐stage ABPA complicating asthma. Thirty subjects were randomised to receive either prednisolone (n = 15, control) or prednisolone and oral vitamin D (n = 15, intervention arm). Serum vitamin D levels were significantly higher in the intervention versus the control arm, following therapy. The mean decline in total IgE at 2 months (primary outcome) was 10% higher in the intervention arm than the control arm; however, this was not statistically significant (48.6% vs 38.1%, P = 0.27). The percentage decline in total IgE after 4 and 6 months of randomisation was also similar in the two arms. There was no difference in asthma exacerbations (0 vs 2, intervention vs control; P = 0.16). No ABPA exacerbation occurred in either arm. The other outcomes including the Th2 (IL‐4, IL‐6 and IL‐10) and Th17 (IL‐17) cytokine levels were similar in the two groups. None of the participants experienced hypervitaminosis D. There was no significant improvement in the clinical or immunological outcomes following vitamin D supplementation. A larger trial is required to ascertain the role of vitamin D in ABPA complicating asthma [Clinicaltrials.gov: NCT03133299].